沙库巴曲缬沙坦钠对慢性心力衰竭合并肺动脉高压患者肺动脉压及心功能的影响  

Effects of Sacubitril Valsartan Sodium on Pulmonary Arterial Pressure and Cardiac Function in Patients with Chronic Heart Failure and Pulmonary Hypertension

作　　者：付幼林 罗骏[1] 张鹏 谢自强 杨忠明[1] FU Youlin;LUO Jun;ZHANG Peng;XIE Ziqiang;YANG Zhongming(Ganzhou People's Hospital,Ganzhou Jiangxi 342100,China)

机构地区：[1]赣州市人民医院,江西赣州342100

出　　处：《药品评价》2022年第10期619-622,共4页Drug Evaluation

基　　金：赣州市指导性科技计划(GZ2016ZSF156)。

摘　　要：目的:探讨沙库巴曲缬沙坦钠对慢性心力衰竭合并肺动脉高压患者肺动脉压及心功能的影响。方法:选择2020年1月至2021年8月赣州市人民医院收治的慢性心衰合并肺动脉高压患者100例,随机分为两组观察组与对照组,各50例。对照组予以缬沙坦治疗,观察组采用沙库巴曲缬沙坦。比较两组治疗效果、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、肺动脉压、6min步行距离及Borg呼吸困难指数。结果:治疗后,观察组治疗总有效率(96.00%)高于对照组(78.00%),LVEF(53.96±6.04)%高于对照组(46.22±4.37)%,LVESD(33.58±1.85)mm、LVEDD(50.68±2.16)mm低于对照组(38.16±2.27)mm、(56.37±2.84)mm,肺动脉压均低于对照组,差异有统计学意义(P<0.05);两组治疗后6 min步行距离均延长,Borg呼吸困难指数均降低,且观察组变化更明显,差异有统计学意义(P<0.05)。结论:慢性心衰合并肺动脉高压患者采用沙库巴曲缬沙坦钠治疗可使治疗效果得到增强,患者心功能指标得到明显改善,肺动脉压得到降低,增强患者运动耐量,降低呼吸困难程度,促进患者康复。Objective:To investigate the effect of sacubitril valsartan sodium on pulmonary arterial pressure and cardiac function in patients with chronic heart failurecomplicated with pulmonary hypertension.Methods:A total of 100 patients with chronic heart failure and pulmonary hypertension who were treated in Ganzhou People’s Hospital from January 2020 to August 2021 were selected and randomly divided into two groups:the observation group and the control group,with 50 cases in each.The control group was treated with valsartan,and the observation group was treated with sacubitril valsartan sodium.The treatment effect,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],pulmonary artery pressure,6 min walking distance and Borg dyspnea index were compared between the two groups.Results:After treatment,the total effective rate(96.00%)of the observation group was higher than that of the control group(78.00%),LVEF(53.96±6.04)%was higher than that of the control group(46.22±4.37)%,LVESD(33.58±1.85)mm,LVEDD(50.68±2.16)mm was lower than the control group(38.16±2.27)mm,(56.37±2.84)mm,and the pulmonary arterial pressure was lower than the control group,the difference was statistically significant(P<0.05).After treatment,6 min walking distance was prdonged in both groups,and the Borg dyspnea index was decreased,and the changes in the observation group were more obvious,and the difference was statistically significant(P<0.05).Conclusion:The treatment effect of sacubitril valsartan sodium in patients with chronic heart failure and pulmonary hypertension can be enhanced,the cardiac function indexes of the patients can be significantly improved,the pulmonary arterial pressure can be reduced,the exercise tolerance of the patients can be enhanced,the degree of dyspnea can be reduced,and the recovery of the patients can be promoted.

关 键 词：心力衰竭 沙库巴曲缬沙坦钠 肺动脉压 心功能 

分 类 号：R541.6[医药卫生—心血管疾病] R544.1[医药卫生—内科学]